Elevated creatine phosphokinase MB in a patient with neuroendocrine carcinoma of the colon―Evidence for a tumor marker: report of a case
Elevated creatine phosphokinase (CPK) MB isoenzyme has become accepted as a highly specific criterion for the diagnosis of myocardial infarction (MI). A patient with metastatic neuroendocrine carcinoma of the colon who had marked and persistent elevation of CPK-MB isoenzyme, in the absence of clinic...
Gespeichert in:
| Veröffentlicht in: | Diseases of the colon & rectum 1988-04, Vol.31 (4), p.318-322 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 322 |
|---|---|
| container_issue | 4 |
| container_start_page | 318 |
| container_title | Diseases of the colon & rectum |
| container_volume | 31 |
| creator | RIZK, S. L ROSEMAN, D. L BONOMI, P SKY-PECK, H CLARK, J INCHUL LEE GOULD, V. E |
| description | Elevated creatine phosphokinase (CPK) MB isoenzyme has become accepted as a highly specific criterion for the diagnosis of myocardial infarction (MI). A patient with metastatic neuroendocrine carcinoma of the colon who had marked and persistent elevation of CPK-MB isoenzyme, in the absence of clinical and cardiographic evidence for MI, is described. The CPK-MB level was 25 percent (normal, less than 3 percent) on admission, 39 percent postoperatively, and 57 percent on discharge. A prompt decline in serum CPK-MB activity (11 percent, less than 3 percent) paralleled chemotherapy-induced tumor regression. Resurgence of the isoenzyme heralded recurrent disease. These findings suggest that CPK-MB may be a valuable adjunct marker in the diagnosis and monitoring of neuroendocrine carcinomas. |
| doi_str_mv | 10.1007/BF02554370 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78183228</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78183228</sourcerecordid><originalsourceid>FETCH-LOGICAL-c185t-f02ae4d9c09e90e635f14a9d45dd89dfab82b75c505a6e6b8ed22dbbf5c305df3</originalsourceid><addsrcrecordid>eNpFkDFPHDEQha0IRA5Ikz6SC5QCacPYPt_upgN0JEigNKFeee2xzmHX3tjei9KlTp8_yC-JT5ygGI1m3jdPo0fIewafGEB9cXUDXMqlqOENWTApoAIhmwOyAGC8KuvVW3Kc0o8yAof6iBwJIdsW2IL8XQ-4VRkN1RFVdh7ptAmp1KPzKiG9v6LOU0WnIqLP9JfLG-pxjgG9CTruLrSK2vkwKhoszZuyCEPwT3_-rbfOoNdIbYjFI89j6aOKjxg_04hTiHl3oopDwlNyaNWQ8N2-n5CHm_X366_V3bcvt9eXd5VmjcyVBa5waVoNLbaAKyEtW6rWLKUxTWus6hve11JLkGqFq75Bw7npeyu1AGmsOCEfn32nGH7OmHI3uqRxGJTHMKeublgjOG8KeP4M6hhSimi7Kbry_e-OQbcLvnsNvsAf9q5zP6J5QfdJF_1sr6uk1WCj8tqlF6yuBdSSi__0YI1w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78183228</pqid></control><display><type>article</type><title>Elevated creatine phosphokinase MB in a patient with neuroendocrine carcinoma of the colon―Evidence for a tumor marker: report of a case</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>SpringerLink Journals - AutoHoldings</source><creator>RIZK, S. L ; ROSEMAN, D. L ; BONOMI, P ; SKY-PECK, H ; CLARK, J ; INCHUL LEE ; GOULD, V. E</creator><creatorcontrib>RIZK, S. L ; ROSEMAN, D. L ; BONOMI, P ; SKY-PECK, H ; CLARK, J ; INCHUL LEE ; GOULD, V. E</creatorcontrib><description>Elevated creatine phosphokinase (CPK) MB isoenzyme has become accepted as a highly specific criterion for the diagnosis of myocardial infarction (MI). A patient with metastatic neuroendocrine carcinoma of the colon who had marked and persistent elevation of CPK-MB isoenzyme, in the absence of clinical and cardiographic evidence for MI, is described. The CPK-MB level was 25 percent (normal, less than 3 percent) on admission, 39 percent postoperatively, and 57 percent on discharge. A prompt decline in serum CPK-MB activity (11 percent, less than 3 percent) paralleled chemotherapy-induced tumor regression. Resurgence of the isoenzyme heralded recurrent disease. These findings suggest that CPK-MB may be a valuable adjunct marker in the diagnosis and monitoring of neuroendocrine carcinomas.</description><identifier>ISSN: 0012-3706</identifier><identifier>EISSN: 1530-0358</identifier><identifier>DOI: 10.1007/BF02554370</identifier><identifier>PMID: 3359901</identifier><identifier>CODEN: DICRAG</identifier><language>eng</language><publisher>Secaucus, NJ: Springer</publisher><subject>Biological and medical sciences ; Biomarkers, Tumor - blood ; Carcinoma - enzymology ; Carcinoma - pathology ; Carcinoma - therapy ; Colon - pathology ; Colonic Neoplasms - enzymology ; Colonic Neoplasms - pathology ; Colonic Neoplasms - therapy ; Creatine Kinase - blood ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Isoenzymes ; Male ; Medical sciences ; Middle Aged ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Tumors</subject><ispartof>Diseases of the colon & rectum, 1988-04, Vol.31 (4), p.318-322</ispartof><rights>1988 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c185t-f02ae4d9c09e90e635f14a9d45dd89dfab82b75c505a6e6b8ed22dbbf5c305df3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7730752$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3359901$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RIZK, S. L</creatorcontrib><creatorcontrib>ROSEMAN, D. L</creatorcontrib><creatorcontrib>BONOMI, P</creatorcontrib><creatorcontrib>SKY-PECK, H</creatorcontrib><creatorcontrib>CLARK, J</creatorcontrib><creatorcontrib>INCHUL LEE</creatorcontrib><creatorcontrib>GOULD, V. E</creatorcontrib><title>Elevated creatine phosphokinase MB in a patient with neuroendocrine carcinoma of the colon―Evidence for a tumor marker: report of a case</title><title>Diseases of the colon & rectum</title><addtitle>Dis Colon Rectum</addtitle><description>Elevated creatine phosphokinase (CPK) MB isoenzyme has become accepted as a highly specific criterion for the diagnosis of myocardial infarction (MI). A patient with metastatic neuroendocrine carcinoma of the colon who had marked and persistent elevation of CPK-MB isoenzyme, in the absence of clinical and cardiographic evidence for MI, is described. The CPK-MB level was 25 percent (normal, less than 3 percent) on admission, 39 percent postoperatively, and 57 percent on discharge. A prompt decline in serum CPK-MB activity (11 percent, less than 3 percent) paralleled chemotherapy-induced tumor regression. Resurgence of the isoenzyme heralded recurrent disease. These findings suggest that CPK-MB may be a valuable adjunct marker in the diagnosis and monitoring of neuroendocrine carcinomas.</description><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoma - enzymology</subject><subject>Carcinoma - pathology</subject><subject>Carcinoma - therapy</subject><subject>Colon - pathology</subject><subject>Colonic Neoplasms - enzymology</subject><subject>Colonic Neoplasms - pathology</subject><subject>Colonic Neoplasms - therapy</subject><subject>Creatine Kinase - blood</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Isoenzymes</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Tumors</subject><issn>0012-3706</issn><issn>1530-0358</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkDFPHDEQha0IRA5Ikz6SC5QCacPYPt_upgN0JEigNKFeee2xzmHX3tjei9KlTp8_yC-JT5ygGI1m3jdPo0fIewafGEB9cXUDXMqlqOENWTApoAIhmwOyAGC8KuvVW3Kc0o8yAof6iBwJIdsW2IL8XQ-4VRkN1RFVdh7ptAmp1KPzKiG9v6LOU0WnIqLP9JfLG-pxjgG9CTruLrSK2vkwKhoszZuyCEPwT3_-rbfOoNdIbYjFI89j6aOKjxg_04hTiHl3oopDwlNyaNWQ8N2-n5CHm_X366_V3bcvt9eXd5VmjcyVBa5waVoNLbaAKyEtW6rWLKUxTWus6hve11JLkGqFq75Bw7npeyu1AGmsOCEfn32nGH7OmHI3uqRxGJTHMKeublgjOG8KeP4M6hhSimi7Kbry_e-OQbcLvnsNvsAf9q5zP6J5QfdJF_1sr6uk1WCj8tqlF6yuBdSSi__0YI1w</recordid><startdate>198804</startdate><enddate>198804</enddate><creator>RIZK, S. L</creator><creator>ROSEMAN, D. L</creator><creator>BONOMI, P</creator><creator>SKY-PECK, H</creator><creator>CLARK, J</creator><creator>INCHUL LEE</creator><creator>GOULD, V. E</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198804</creationdate><title>Elevated creatine phosphokinase MB in a patient with neuroendocrine carcinoma of the colon―Evidence for a tumor marker: report of a case</title><author>RIZK, S. L ; ROSEMAN, D. L ; BONOMI, P ; SKY-PECK, H ; CLARK, J ; INCHUL LEE ; GOULD, V. E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c185t-f02ae4d9c09e90e635f14a9d45dd89dfab82b75c505a6e6b8ed22dbbf5c305df3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoma - enzymology</topic><topic>Carcinoma - pathology</topic><topic>Carcinoma - therapy</topic><topic>Colon - pathology</topic><topic>Colonic Neoplasms - enzymology</topic><topic>Colonic Neoplasms - pathology</topic><topic>Colonic Neoplasms - therapy</topic><topic>Creatine Kinase - blood</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Isoenzymes</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RIZK, S. L</creatorcontrib><creatorcontrib>ROSEMAN, D. L</creatorcontrib><creatorcontrib>BONOMI, P</creatorcontrib><creatorcontrib>SKY-PECK, H</creatorcontrib><creatorcontrib>CLARK, J</creatorcontrib><creatorcontrib>INCHUL LEE</creatorcontrib><creatorcontrib>GOULD, V. E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diseases of the colon & rectum</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RIZK, S. L</au><au>ROSEMAN, D. L</au><au>BONOMI, P</au><au>SKY-PECK, H</au><au>CLARK, J</au><au>INCHUL LEE</au><au>GOULD, V. E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elevated creatine phosphokinase MB in a patient with neuroendocrine carcinoma of the colon―Evidence for a tumor marker: report of a case</atitle><jtitle>Diseases of the colon & rectum</jtitle><addtitle>Dis Colon Rectum</addtitle><date>1988-04</date><risdate>1988</risdate><volume>31</volume><issue>4</issue><spage>318</spage><epage>322</epage><pages>318-322</pages><issn>0012-3706</issn><eissn>1530-0358</eissn><coden>DICRAG</coden><abstract>Elevated creatine phosphokinase (CPK) MB isoenzyme has become accepted as a highly specific criterion for the diagnosis of myocardial infarction (MI). A patient with metastatic neuroendocrine carcinoma of the colon who had marked and persistent elevation of CPK-MB isoenzyme, in the absence of clinical and cardiographic evidence for MI, is described. The CPK-MB level was 25 percent (normal, less than 3 percent) on admission, 39 percent postoperatively, and 57 percent on discharge. A prompt decline in serum CPK-MB activity (11 percent, less than 3 percent) paralleled chemotherapy-induced tumor regression. Resurgence of the isoenzyme heralded recurrent disease. These findings suggest that CPK-MB may be a valuable adjunct marker in the diagnosis and monitoring of neuroendocrine carcinomas.</abstract><cop>Secaucus, NJ</cop><pub>Springer</pub><pmid>3359901</pmid><doi>10.1007/BF02554370</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-3706 |
| ispartof | Diseases of the colon & rectum, 1988-04, Vol.31 (4), p.318-322 |
| issn | 0012-3706 1530-0358 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78183228 |
| source | MEDLINE; Journals@Ovid Complete; SpringerLink Journals - AutoHoldings |
| subjects | Biological and medical sciences Biomarkers, Tumor - blood Carcinoma - enzymology Carcinoma - pathology Carcinoma - therapy Colon - pathology Colonic Neoplasms - enzymology Colonic Neoplasms - pathology Colonic Neoplasms - therapy Creatine Kinase - blood Gastroenterology. Liver. Pancreas. Abdomen Humans Isoenzymes Male Medical sciences Middle Aged Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tumors |
| title | Elevated creatine phosphokinase MB in a patient with neuroendocrine carcinoma of the colon―Evidence for a tumor marker: report of a case |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T08%3A40%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elevated%20creatine%20phosphokinase%20MB%20in%20a%20patient%20with%20neuroendocrine%20carcinoma%20of%20the%20colon%E2%80%95Evidence%20for%20a%20tumor%20marker:%20report%20of%20a%20case&rft.jtitle=Diseases%20of%20the%20colon%20&%20rectum&rft.au=RIZK,%20S.%20L&rft.date=1988-04&rft.volume=31&rft.issue=4&rft.spage=318&rft.epage=322&rft.pages=318-322&rft.issn=0012-3706&rft.eissn=1530-0358&rft.coden=DICRAG&rft_id=info:doi/10.1007/BF02554370&rft_dat=%3Cproquest_cross%3E78183228%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78183228&rft_id=info:pmid/3359901&rfr_iscdi=true |